Kenvue IncNYSE: KVUE
Consumer Staples · Personal Care Products
$18.29
+4.73%
Vol: 730K
Research Digest
Monday, June 15, 2026
No significant overnight updates
No material news in the last 48 hours.
Previous Market Intelligence
13 daysJun 14No significant overnight updatesNeutral▶
No material news in the last 48 hours.
May 21Kenvue Q1 beats; Annual Meeting May 21 amid Kimberly-Clark mergerNeutral▶
Q1 2026 net sales $3.82-3.91B (+3-4.5% YoY), net income $474M, adj EPS $0.48 matching guidance. Skin Health & Beauty (Neutrogena, Aveeno) drove growth. No earnings call due to pending Kimberly-Clark transaction. FY26 guide reaffirmed: 2.5-4.0% revenue growth, adj EPS $1.85-$1.95. Dividend $0.21 paid May 27. Annual Meeting May 21, 2026. Analysts skeptical on KMB merger value; PTs around $19-20.
May 20No significant overnight updatesNeutral▶
No material news in the last 48 hours.
May 19Kenvue (KVUE) stock highlighted as institutional-flow tactical indicator on May 17 as Kimberly-Clark merger approaches mid-2026 close.Neutral▶
On May 17, 2026, KVUE was featured by Stock Traders Daily as a liquidity-pulse indicator for institutional positioning ahead of the pending Kimberly-Clark merger, which both shareholder bases approved in January 2026 and is targeted for completion in H2 2026. Recent fundamentals (Q1 net sales +4.5%, EPS $0.25 +47% YoY) and a $0.21 May 13 ex-dividend reinforce the steady-state thesis until deal close. This matters because pre-close arb spreads and event risk dominate near-term KVUE price action. Bear case: regulatory delays or deal-term renegotiation could break the merger narrative; pet-/consumer-staples demand remains soft.
May 18Kenvue beat Q1 estimates with adjusted EPS of $0.48 as Kimberly-Clark merger progresses, with General Counsel exiting stake.Mixed▶
Kenvue's General Counsel Matthew Orlando sold 38,491 shares of common stock in an open-market transaction on May 8, 2026 at a weighted-average price of $17.66 per share, fully exiting his stake. The Q1 2026 results reported May 7 showed sales of $3.82 billion (up 3.1% YoY), with adjusted EPS of $0.48 beating the consensus of $0.26-$0.32. Skin Health & Beauty (Neutrogena, Aveeno) drove growth, and full-year 2026 guidance remains anchored at revenue growth of 2.5%-4.0% and adjusted EPS of $1.85-$1.95. The pending $48.7 billion acquisition by Kimberly-Clark continues to progress, with Kenvue forgoing its quarterly conference call. A quarterly dividend of $0.2075 per share was paid May 27, 2026. Analysts upgraded the stock, citing stronger consumer health portfolio performance, with implied fair value around $19.75.
May 15Kenvue General Counsel Matthew Orlando sold 38,491 shares May 8 exiting his entire direct stake, as the pending $40B Kimberly-Clark acquisition advances with US antitrust approval and is on track to close 2H 2026.Mixed▶
Kenvue reported Q1 2026 sales of $3.91B (up 4.5%) with organic sales up 0.7% and diluted EPS of $0.25, up from $0.17 prior year. Gross margin expanded to 58.9% (adjusted 60.8%), operating margin rose to 19.6% (adjusted 24.0%). Board declared a $0.2075 quarterly dividend payable May 27 to holders of record May 13. The Kimberly-Clark acquisition has received shareholder and major US antitrust approvals, on track to close in 2H 2026. On May 8, GC Matthew Orlando sold 38,491 shares in open-market sale, leaving zero directly owned KVUE common stock. J.P. Morgan upgraded to Buy with $32.50 PT on May 5. Risk: deal break premium evaporates if regulatory approval stalls; insider exit raises optical concern.
May 14Kenvue reports Q1 2026 sales of $3.91B and net income of $474M ahead of Kimberly-Clark merger close, with BofA upgrading to Buy at $32.50 target.Positive▶
Kenvue reported Q1 2026 results on May 7 with sales of $3.91B (up 4.5% YoY, organic growth +0.7%, FX +3.8%) and net income of $474M ($0.25 EPS from continuing operations). Gross margin improved to 58.9% from 58.0%, and free cash flow rose to $0.4B from $0.2B. The pending merger with Kimberly-Clark, announced November 2, 2025, was approved by both companies' shareholders on January 29, 2026, with Kimberly-Clark acquiring all outstanding Kenvue shares in a cash-and-stock deal. The Board approved a restructuring program on February 17 expected to incur about $250M in pre-tax charges in fiscal 2026. BofA upgraded to Buy with a $32.50 target on May 5, joined Zacks Strong Buy list. Stock trading around $17.43.
May 13Kenvue's General Counsel sold 38,491 shares on May 8 as the company progresses toward its $48.7B acquisition by Kimberly-Clark expected to close in H2 2026.Mixed▶
Kenvue General Counsel Matthew Orlando sold 38,491 shares on May 8, 2026, at an average price of $17.66. The company recently reported Q1 2026 results: $0.32 EPS beating the $0.27 consensus, and revenue of $3.91 billion (+4.5% YoY) above the $3.84 billion estimate, with gross margin expanding to 58.9%. Kenvue continues to progress toward closing its $48.7 billion definitive merger with Kimberly-Clark, which shareholders approved in late January 2026 and which is expected to close in the second half of 2026. The board approved a 2026 Restructuring Initiative with ~$250 million in pre-tax charges to optimize the operating model and supply chain. A separate analyst upgrade on May 5 raised KVUE's rating from Hold to Buy with a $32.50 price target. A $0.2075 dividend is payable May 27.
May 12Kenvue rallies on Q1 EPS beat and Buy upgrade as Kimberly-Clark merger approval clearance progressesPositive▶
Kenvue beat Q1 2026 estimates with $0.32 EPS, 4.5% sales growth, and strong margin expansion (+47% EPS YoY). Self Care sales rose 1.9%, Skin Health and Beauty up 8.4%, and Essential Health up 4.9%. Shares traded at $28.40 on May 7, up 4.2% over five sessions following analyst upgrades. A May 5 upgrade lifted KVUE from Hold to Buy with $32.50 target, while Bank of America rates Buy at $31. Forward guidance withheld due to pending Kimberly-Clark $48.7B acquisition, which received shareholder approvals and U.S. antitrust clearance, expected to close H2 2026. Quarterly dividend of $0.21 goes ex May 13.
May 11Kenvue posted Q1 EPS beat of $0.32 (19.9% surprise) with JPMorgan upgrade to Buy at $32.50 target ahead of pending Kimberly-Clark merger closePositive▶
Kenvue reported Q1 2026 results on May 7 with adjusted EPS of $0.32, a 19.9% beat versus estimates, and revenue of $3.78 billion (net sales up 4.5%, organic growth 0.7%, FX benefit 3.8%). Gross margin expanded to 58.9% from 58.0%. Free cash flow doubled YoY to $0.4 billion. No earnings call was held due to the pending $48.7 billion Kimberly-Clark acquisition approved by shareholders in January 2026. The 2026 Restructuring Initiative is projected to cost ~$250 million pre-tax. JPMorgan upgraded KVUE to Buy on May 5 with a $32.50 price target. BofA upgraded to Buy at $31 in early April. KVUE declared a $0.207 dividend with ex-date May 13.
May 8Kenvue Q1 earnings beat on 33% EPS growth amid Kimberly-Clark acquisitionPositive▶
Kenvue reported strong Q1 2026 results with net sales up 4.5%, adjusted diluted EPS up 33% to $0.32, and diluted EPS up 47% to $0.25. Gross margin improved to 58.9% with adjusted gross margin at 60.8%. Free cash flow doubled to $0.4B. Skin Health segment drove growth with 8.4% net sales increase. Kimberly-Clark acquisition remains on track for close in H2 2026.
May 7Kenvue Q1 boosts margins ahead of Kimberly-Clark acquisition expected H2 2026Mixed▶
Kenvue reported Q1 net sales up 4.5% YoY with organic growth of 0.7%. Adjusted diluted EPS rose to $0.32 from $0.24. Gross margin improved to 58.9% from 58.0%. Kimberly-Clark acquisition shareholder vote approved 99% with deal expected to close H2 2026, creating $32B combined entity. Free cash flow doubled to $0.4B showing strong operational improvements.
May 6Kimberly-Clark to acquire Kenvue in $48.7B deal; interim CFO transitionMixed▶
Kimberly-Clark announced definitive agreement to acquire Kenvue in cash-and-stock transaction valuing company at $48.7B enterprise value. Deal expected to close H2 2026. Heather Howlett became interim CFO effective May 12, 2026, replacing Amit Banati who departed for CEO role. Kenvue reports Q1 earnings May 7. Analyst sentiment mixed with recent downgrades: Citi lowered PT to $19 from $20, Barclays to $18 from $19. Stock trading at $17.43 with 4.8% dividend yield.
Sector Peers
| Company | Price | Day | 1M | Fwd P/E | Beta | Mkt Cap |
|---|---|---|---|---|---|---|
| PGPROCTER | $149.99 | +4.60% | +0.7% | 20.2x | 0.40 | $333.9B |
| KVUEKENVUE | $18.29 | +4.73% | +1.6% | 14.2x | 0.52 | $33.5B |
| ELESTEE | $90.90 | +15.19% | -1.4% | 24.8x | 1.21 | $28.5B |
| WMTWALMART | $119.55 | -1.48% | -9.0% | 36.8x | 0.65 | $967.2B |
| COSTCOSTCO | $973.70 | -7.31% | -2.4% | 46.6x | 0.91 | $466.0B |
| KOCOCA | $80.93 | -0.30% | -0.0% | 23.3x | 0.36 | $349.2B |
Key Fundamentals
RSI (14-Day)
52-Week Range
Moving Averages
Price above both MAs — bullish structure.